SSRI Medications Compared: A Side-by-Side Look at the Major Options

Choosing between SSRIs is not as simple as picking a serotonin reuptake inhibitor and waiting. All six major options in the class share the same primary mechanism. What separates them are the pharmacological details that most prescribers weigh carefully before writing the first prescription: half-life, receptor selectivity, enzyme inhibition, discontinuation risk, and the side effect profile that is most likely to matter for this specific patient.

Your brain’s serotonin system does not work as a uniform dial. Different SSRIs interact with different enzymes, have different rates of elimination, and carry different off-target receptor activities that produce different side effects at therapeutic doses. The medications that work through identical primary mechanisms can behave very differently in practice.

What This Page Covers

• How SSRIs work and why mechanism differences matter clinically
• A profile of each major SSRI: indications, half-life, interactions, and key side effects
• What determines which SSRI a prescriber chooses for a specific patient
• Sexual dysfunction rates and options
• Discontinuation syndrome: which drugs are highest and lowest risk
• How continuous monitoring changes what becomes clinically visible

How SSRIs Work

All SSRIs block the serotonin transporter (SERT), the protein that pulls serotonin back into the presynaptic neuron after it is released. By preventing that reuptake, SSRIs increase the availability of serotonin in the synaptic cleft. This effect happens within hours of the first dose. The clinical effect, meaningful symptom improvement, typically takes four to eight weeks.

A 2018 Lancet network meta-analysis of 522 trials and 116,477 participants confirmed that all 21 antidepressants studied were more efficacious than placebo for acute treatment of major depressive disorder in adults. Among SSRIs specifically, escitalopram and sertraline showed the best balance of response rates and acceptability, meaning fewer patients stopped them due to side effects.

The delayed clinical effect suggests that SERT inhibition alone is not the complete story. Downstream changes in receptor density, neuroplasticity, and second-messenger systems appear to be what actually shifts mood and anxiety over time.

The Major SSRIs: Drug-by-Drug Profiles

Fluoxetine (Prozac)

The first SSRI approved in the United States (1987), fluoxetine is still among the most prescribed. It has FDA approval for major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, bipolar depression (in combination with olanzapine), and premenstrual dysphoric disorder.

Its defining pharmacological feature is a very long half-life. The parent compound has a half-life of 1 to 4 days. Its active metabolite, norfluoxetine, has a half-life of 4 to 16 days. Because of this extended half-life, fluoxetine essentially tapers itself when stopped, which is why it has the lowest rate of discontinuation syndrome among commonly prescribed SSRIs. However, the same long half-life means that fluoxetine takes the longest to clear from the body. A 14-day washout period is required before starting an MAOI after fluoxetine, versus only 7 days for most other SSRIs.

Fluoxetine is also a strong CYP2D6 inhibitor, which means it can substantially raise plasma levels of many other medications. It is more activating than most SSRIs. Patients with insomnia or anxiety may experience worsening sleep or jitteriness early in treatment.

Sertraline (Zoloft)

Sertraline has the broadest FDA indication set: major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder. It is one of the most frequently prescribed SSRIs globally.

The Cipriani 2018 Lancet analysis identified sertraline as among the most favorable SSRIs in terms of the ratio of efficacy to acceptability. It has moderate CYP2D6 inhibition, lower than paroxetine or fluoxetine, but still worth tracking in polypharmacy situations. Gastrointestinal side effects, particularly diarrhea, are more common with sertraline than with most other SSRIs.

Among patients who need antidepressant treatment during pregnancy, sertraline has one of the larger safety datasets and is often considered a preferred option.

Escitalopram (Lexapro)

Escitalopram is the pure S-enantiomer of citalopram and is considered the most selective SSRI in terms of receptor binding. It has FDA approval for major depressive disorder and generalized anxiety disorder.

The CANMAT 2023 updated clinical guidelines for management of major depressive disorder identified escitalopram, along with agomelatine and vortioxetine, as showing advantages over other antidepressants when both efficacy and acceptability are considered together. Escitalopram has minimal CYP450 inhibition, making it one of the cleanest options for patients on multiple medications. It has a moderate half-life of approximately 27 to 32 hours.

The dosing range is narrow: 10 mg is the starting dose and the standard therapeutic dose; 20 mg is the maximum. A fixed-dose FDA trial found no statistically significant advantage of 20 mg over 10 mg overall, though individual patients with inadequate response at 10 mg often benefit from the increase.

Citalopram (Celexa)

Citalopram is the racemic parent of escitalopram. It has FDA approval for major depressive disorder. The practical distinction from escitalopram is primarily the dose ceiling: the FDA issued a safety communication in 2011 limiting citalopram to 40 mg per day for most adults because of QT interval prolongation at higher doses, with a 20 mg ceiling for patients over 60, those with hepatic impairment, and CYP2C19 poor metabolizers.

Like escitalopram, citalopram has low CYP450 inhibition potential, making it well-suited for patients on multiple drugs. It carries slightly higher rates of dry mouth and sedation than escitalopram.

Paroxetine (Paxil)

Paroxetine has the most FDA-approved indications in the SSRI class, covering major depressive disorder, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder.

It is also the SSRI with the most significant side effect considerations. A prospective multicenter study (the SALSEX study) of 1,022 outpatients found that paroxetine caused sexual dysfunction in 70.7% of patients when assessed systematically, one of the highest rates in the class. Paroxetine is associated with the most weight gain of any SSRI, particularly with long-term use.

Paroxetine is a strong CYP2D6 inhibitor and a strong inhibitor of its own metabolism at higher doses (autoinhibition), which complicates dose titration. Its short half-life and lack of an active metabolite make it the SSRI most likely to produce severe discontinuation syndrome when stopped abruptly or when doses are missed.

It is specifically discouraged during pregnancy due to observational data suggesting an association with cardiac malformations, though the absolute risk remains small.

Fluvoxamine (Luvox)

Fluvoxamine has FDA approval for obsessive-compulsive disorder (the indication for which it is primarily used) and is sometimes prescribed off-label for depression and social anxiety. It has a unique pharmacological profile: it is among the most potent inhibitors of multiple CYP enzymes (1A2, 2C19, 3A4), making it the SSRI with the highest drug interaction potential. Caffeine metabolism, clozapine metabolism, and several other drug pathways are significantly affected by fluvoxamine.

Gastrointestinal side effects, particularly nausea, are notably higher with fluvoxamine than with other SSRIs. Discontinuation rates due to adverse effects are also among the highest in the class.

What Guides SSRI Selection

Several clinical factors typically influence the initial SSRI choice:

Comorbid conditions. Fluoxetine’s bulimia approval makes it the only SSRI recommended for that indication. Paroxetine covers all five anxiety disorder indications. Sertraline’s PTSD approval, combined with its safety data in pregnancy, makes it a common first choice for patients of childbearing age with trauma history.

Drug interactions. Patients on medications metabolized by CYP2D6 (including many antiarrhythmics, antipsychotics, and opioid analgesics) need to avoid strong inhibitors like paroxetine and fluoxetine. Citalopram and escitalopram are preferred in complex polypharmacy situations.

Side effect priorities. For patients particularly concerned about weight, fluoxetine has the most favorable short-term profile. For patients with preexisting sexual dysfunction concerns, escitalopram tends to have lower rates than paroxetine or citalopram. For patients at risk of falls (older adults), avoiding paroxetine’s anticholinergic and sedating effects is generally recommended.

Discontinuation risk. For patients who are likely to have irregular adherence or who may need to stop quickly for medical reasons, fluoxetine’s self-tapering pharmacokinetics are a clinical asset.

Cardiac history. Citalopram at doses above 40 mg carries QT prolongation risk. Patients with known QT prolongation, hypokalemia, or concurrent QT-prolonging drugs should use citalopram cautiously and within the dose ceiling.

Sexual Side Effects

Sexual dysfunction is among the most common reasons patients quietly stop SSRIs without telling their prescriber. Studies using direct questionnaire assessment find rates of 60 to 80% across the SSRI class, compared to much lower rates reported spontaneously.

Rates differ across drugs. The SALSEX study found paroxetine at 70.7%, citalopram at 72.7%, sertraline at 62.9%, and fluoxetine at 57.7%. The common mechanism involves serotonin suppression of dopamine activity (reducing libido), nitric oxide inhibition (reducing genital arousal), and 5-HT2 receptor stimulation (delaying orgasm).

When sexual side effects become a barrier to adherence, adjunctive bupropion 150 to 300 mg has the strongest evidence for reversing SSRI-induced sexual dysfunction in both men and women across the domains of desire, arousal, and orgasm. Read more about SSRI sexual side effects and what patients can do.

Discontinuation Syndrome

Discontinuation syndrome refers to the cluster of symptoms that can emerge when SSRIs are stopped abruptly or doses are frequently missed: dizziness, flu-like symptoms, electric shock sensations, anxiety, and irritability. Discontinuation syndrome is most common with SSRIs that have shorter half-lives and no active metabolites, particularly paroxetine, sertraline, and fluvoxamine. Fluoxetine has the lowest risk due to its self-tapering pharmacokinetics.

Managing discontinuation requires gradual tapering, with the rate tailored to the specific SSRI and the duration of treatment. Paroxetine often requires the slowest taper.

What Daily Monitoring Changes

A single appointment every three months captures a snapshot. It does not capture which side effect made the patient consider stopping on week four, which symptom cluster responded first, or the pattern of missed doses that explains the apparent partial response. That data lives between visits.

“The first few weeks on an SSRI are when the most important clinical information is generated, and it is almost never collected systematically,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “Which side effects are tolerable, which are not, whether the activation is getting better or worse, whether sleep is improving or disrupting, and whether there is any early signal of response. When I have that data from daily check-ins, I can intervene before a patient quietly stops.”

What Members Are Saying

DM

D.M., 38

Major Depressive Disorder

“I had been on two different SSRIs over five years with no consistent follow-up between appointments. When I started with SiggyMD, the daily check-ins caught that I was experiencing significant sexual side effects I had never mentioned to anyone. Within three weeks my prescriber had a clear picture and adjusted my plan. It made a real difference.”

KP

K.P., 52

Generalized Anxiety Disorder

“I switched from one SSRI to another twice because of side effects. Each time it was a guessing process at my quarterly appointment. The ongoing check-ins mean my prescriber actually knows how I am doing day to day, not just how I remember feeling a week before the visit.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Bottom Line

The six major SSRIs differ meaningfully in half-life, drug interaction potential, side effect burden, and discontinuation risk. Efficacy differences are modest but real. Escitalopram and sertraline have the most favorable overall profiles across multiple analyses. Paroxetine carries the highest side effect burden. Fluoxetine’s long half-life is both an asset (minimal discontinuation risk) and a constraint (longest washout period, significant interactions).

The right SSRI for a given patient depends on their comorbid conditions, other medications, side effect tolerability, and clinical history. That decision benefits from data collected between visits, not just what can be reconstructed from memory at a quarterly appointment. Start your anonymous intake with SiggyMD to get a treatment plan reviewed by a licensed prescriber who tracks your response over time, not just at the next appointment. You can also learn more about why antidepressants sometimes stop working and what the clinical options are.

Sources

• Cipriani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018;391(10128):1357-1366.

• Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. The Canadian Journal of Psychiatry. 2024;69(9):641-687.

• Shin JJ, Saadabadi A. Trazodone. StatPearls. NIH National Library of Medicine. Updated February 2024.

• Tharmalingam S, Arumugham SS. Treatment-Emergent Sexual Dysfunctions Due to Antidepressants: A Primer on Assessment and Management Strategies. Indian Journal of Psychiatry. 2024;66(3):293-303.

• Rizvi SJ, Kennedy SH. Managing SSRI-Induced Sexual Dysfunction. Journal of Psychiatry and Neuroscience. 2013;38(5).

• Safak O, et al. Antidepressant-Associated Sexual Dysfunction in Outpatients. BMC Psychiatry. 2025;25:175.

• FDA. Drug Safety Communication: Revised Recommendations for Celexa (citalopram hydrobromide). 2012.